Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
featured
CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

  • 176 views
  • 08 Nov, 2020
  • 1 location
A Prospective Study of Neoadjuvant Chemotherapy With Gemcitabine/Platinum in Muscle-Invasive or Locally-Advanced Urothelial Carcinoma of Bladder

Previously-untreated, high-risk (>T3 and/or N+) muscle-invasive bladder cancer (MIBC) cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1

  • 2 views
  • 23 Jan, 2021
  • 1 location
Combination Therapy With Pembrolizumab and sEphB4-HSA in Previously Treated Urothelial Carcinoma

This phase II trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with urothelial (bladder) cancer that has spread from the primary site to other places in the body or has come back and does not respond to certain chemotherapy drugs. Combinations of biological substances …

  • 3 views
  • 22 Jan, 2021
  • 2 locations
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma. Whenever possible, a new bone lesion or new/progressing soft tissue lesion will be chosen for biopsy as opposed to radiographically stable lesion. Patients will …

carcinoma
testosterone level
metastasis
prostate carcinoma
gonadotropin
  • 7 views
  • 04 Jun, 2021
  • 1 location
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors. Immunotherapy with monoclonal antibodies, such as avelumab, durvalumab, pembrolizumab, atezolizumab, and nivolumab, may help the body's immune …

  • 0 views
  • 22 Aug, 2021
  • 284 locations
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously …

pd-l1
lymphoma
lung cancer
metastasis
merkel cell carcinoma
  • 1813 views
  • 22 Mar, 2021
  • 47 locations
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

The purpose of this study is to test the safety and effectiveness of immunotherapy (checkpoint inhibitor therapy) in advanced bladder cancer when given intermittently. An unanswered question with the use of CPI (checkpoint inhibitor) is the duration of therapy required for optimal clinical benefit. In the absence of progressive disease …

advanced urothelial carcinoma
gilbert's syndrome
bladder cancer
avelumab
durvalumab
  • 0 views
  • 17 Jul, 2021
  • 1 location
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma

This phase II trial studies how well neutron radiation therapy and pembrolizumab work in treating participants with urothelial carcinoma that has spread to other places in the body. Neutron radiation therapy uses high energy neutrons to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may …

advanced urothelial carcinoma
systemic therapy
metastasis
neutrophil count
cancer
  • 0 views
  • 30 Jun, 2021
  • 1 location
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

This is an open label, non-randomized phase 2 study of the combination of pembrolizumab and cabozantinib to assess overall response rate (ORR), progression free survival at 6 months (PFS6), and overall survival (OS) in patients with metastatic urothelial carcinoma (UC) ineligible for cisplatin.

carcinoma
advanced urothelial carcinoma
metastasis
transitional cell carcinoma
metastatic urothelial carcinoma
  • 22 views
  • 14 Aug, 2021
  • 3 locations
Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma

The objective is to investigate the efficacy and safety of four cycles of ddMVAC with G-CSF support in patients with MIBC and locally advanced UC

g-csf
advanced urothelial carcinoma
metastasis
bladder cancer
transurethral resection of bladder tumor
  • 1 views
  • 24 Jan, 2021
  • 1 location